The objective of this study was to determine whether screening for prostate cancer (PC) reduces PC mortality and, if so, whether the required criteria to be introduced as a population-based screening program are satisfied. A literature review was conducted through electronic scientific databases. The screening tests, that is, PSA and digital rectal examination, have limited sensitivity and specificity for detecting PC; screening produces a beneficial stage shift and reduces PC mortality. Nevertheless, PC screening causes a large increase in the cumulative incidence, and the understanding of the economic cost and quality-of-life parameters are limited. PC screening cannot be justified yet in the context of a public health policy.

DRE, Early detection, Mass screening, Mortality, PSA, antigen detection, cancer chemotherapy, cancer diagnosis, cancer grading, cancer mortality, cancer prevention, cancer screening, clinical trial, digital rectal examination, dutasteride, finasteride, human, lung cancer, occult blood test, placebo, prediction, priority journal, prostate biopsy, prostate cancer, prostate specific antigen, quality of life, review, risk reduction, screening test, sensitivity and specificity, steroid 5alpha reductase inhibitor, uterine cervix cancer
dx.doi.org/10.1038/pcan.2010.14, hdl.handle.net/1765/20854
Prostate Cancer and Prostatic Diseases
Erasmus MC: University Medical Center Rotterdam

van Leeuwen, P.J, van Vugt, H.A, & Bangma, C.H. (2010). The implementation of screening for prostate cancer. Prostate Cancer and Prostatic Diseases (Vol. 13, pp. 218–227). doi:10.1038/pcan.2010.14